Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

BCMA bispecifics: breaking the chains of resistance

Johannes M. Waldschmidt, Leo Rasche

Blood (2024) 144 (25): 2566–2568.

https://doi.org/10.1182/blood.2024026932

Published: 2024

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2024-202348

Published: 2024

Journal Articles

Visualization of Bortezomib Induced Peripheral Neuropathy By Dorsal Root Ganglion MRI in Patients with Multiple Myeloma

Xiang Zhou, Magnus Schindehuette, Nadine Cebulla, Baran Öztürk, Simon Weiner, Julia Mersi, Leo Rasche, Johannes Waldschmidt, Hermann Einsele, Robert Blum, Heike Rittner, Claudia Sommer, Mirko Pham, Martin K. Kortüm

Blood (2024) 144 (Supplement 1): 7580.

https://doi.org/10.1182/blood-2024-210374

Published: 2024

Journal Articles

Implementing Hifi Sequencing for Enhanced Genomic and Methylome Characterization in Multiple Myeloma

Seungbin Han, Nazia Afrin, Bas Tolhuis, Marietta Truger, Peter Raab, Umair Munawar, Cornelia Vogt, Shilpa Kurian, Silvia Nerreter, Xiang Zhou, Claudia Haferlach, Hermann Einsele, Johannes Waldschmidt, Leo Rasche, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 7490.

https://doi.org/10.1182/blood-2024-207422

Published: 2024

Journal Articles

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

Seungbin Han, Chien-Yun Lee, Lenka Besse, Umair Munawar, Andrej Besse, Ann-Sohpie Hainold, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Xiang Zhou, Larissa Haertle, Johannes Waldschmidt, Christoph Driessen, Hermann Einsele, Leo Rasche, Bernhard Kuster, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 6817.

https://doi.org/10.1182/blood-2024-203352

Published: 2024

Journal Articles

GLUT1 Expressing Circulating Normal and Malignant Plasma Cells Predict Multiple Myeloma Progression

Paula Tabares, Vincent Petit, Nupur Bhatnagar, Antonio Giovanni Solimando, Jayabhuvaneshwari Dhanraj, Alexis Gonzalez-Diaz, Sanisha Sunuwar, Katharina Schmiedgen, Celia Cartagena, Hüsniye Dagdeviren, Vanessa Desantis, Robin Scheler-Eckstein, Martin K. Kortüm, Leo Rasche, Johannes Waldschmidt, Christian Pinset, Caroline Rougé Dubroc, Hermann Einsele, Andreas Beilhack

Blood (2024) 144 (Supplement 1): 6830.

https://doi.org/10.1182/blood-2024-209708

Published: 2024

Journal Articles

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Xiang Zhou, Sarah Wiethe, Angelika Wolff, Max J Steinhardt, Nazia Afrin, Mara John, Christine Riedhammer, Xianghui Xiao, Umair Munawar, Julia Mersi, Seungbin Han, Johannes Waldschmidt, Angela Riedel, Max S. Topp, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Leo Rasche

Blood (2024) 144 (Supplement 1): 4705.

https://doi.org/10.1182/blood-2024-203391

Published: 2024

Journal Articles

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Jennifer Wing Lam Cheung, Prachurjya Panda, Xiang Zhou, Katrin Sinning, Ankit Agrawal, Andy Shing Fung Chan, Johannes Duell, Johannes Waldschmidt, Hermann Einsele, Martin Väth, Andreas Rosenwald, Dominic Grün, Leo Rasche

Blood (2024) 144 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2024-203052

Published: 2024

Journal Articles

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Blood (2024) 144 (Supplement 1): 493.

https://doi.org/10.1182/blood-2024-206003

Published: 2024

Journal Articles

Real-World Confirmatory Analysis of the Current IMWG Diagnostic Criteria Identifies Early Transformation As Major Risk Factor in Plasma Cell Leukemia

Jessica Peter, Sophia Danhof, Xiang Zhou, Maximilian J. Steinhardt, Sven Krippner, Anna Gebauer, Franz Reinhard, Georg Fette, Maximilian Ertl, Hermann Einsele, Julia Mersi, Martin K. Kortüm, Leo Rasche, Johannes Waldschmidt

Blood (2024) 144 (Supplement 1): 6893.

https://doi.org/10.1182/blood-2024-210379

Published: 2024

Journal Articles

Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Anna Fleischer, Mohammad Barakat, Sofie-Katrin Kadel, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, K. Martin Kortüm, Imad Maatouk, Leo Rasche

Blood (2024) 144 (Supplement 1): 284.

https://doi.org/10.1182/blood-2024-205037

Published: 2024

Journal Articles

Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature

Johannes Waldschmidt, Mark Kidd, Sophia Danhof, Martin Schreder, Ignat Drozdov, Cornelia Vogt, Hermann Einsele, Leo Rasche, Abdel Halim, Martin K. Kortüm

Blood (2024) 144 (Supplement 1): 4714.

https://doi.org/10.1182/blood-2024-209995

Published: 2024

Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2024-211833

Published: 2024

Journal Articles

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blood (2024) 144 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2024-211012

Published: 2024

Journal Articles

Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab

Umair Munawar, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Patrick Eiring, Julia Weingart, Xiang Zhou, Markus Sauer, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 593.

https://doi.org/10.1182/blood-2024-200593

Published: 2024

Journal Articles

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2024-210233

Published: 2024

Journal Articles

CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Blood (2024) 144 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2024-209831

Published: 2024

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

NARROW

BCMA bispecifics: breaking the chains of resistance

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Visualization of Bortezomib Induced Peripheral Neuropathy By Dorsal Root Ganglion MRI in Patients with Multiple Myeloma

Implementing Hifi Sequencing for Enhanced Genomic and Methylome Characterization in Multiple Myeloma

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

GLUT1 Expressing Circulating Normal and Malignant Plasma Cells Predict Multiple Myeloma Progression

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Real-World Confirmatory Analysis of the Current IMWG Diagnostic Criteria Identifies Early Transformation As Major Risk Factor in Plasma Cell Leukemia

Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only